- Title
- Inhaled corticosteroid use during pregnancy among women with asthma: a systematic review and meta-analysis
- Creator
- Robijn, Annelies L.; Jensen, Megan E.; McLaughlin, Karen; Gibson, Peter G.; Murphy, Vanessa E.
- Relation
- NHMRC.1084816 http://purl.org/au-research/grants/nhmrc/1084816
- Relation
- Clinical and Experimental Allergy Vol. 49, Issue 11, p. 1403-1417
- Publisher Link
- http://dx.doi.org/10.1111/cea.13474
- Publisher
- Wiley-Blackwell
- Resource Type
- journal article
- Date
- 2019
- Description
- Background: Studies demonstrate the prescription rate for inhaled corticosteroids (ICS) decreases in early pregnancy, possibly increasing exacerbation risk. This could be related to non‐adherence to prescribed asthma medication or medication cessation by the patient or doctor. ICS use during pregnancy has not previously been summarized in a systematic review. Objective: The aim of this systematic review and meta‐analysis was to evaluate the use of ICS during pregnancy among asthmatic women, specifically: (1) the prevalence of use, (2) changes of use during pregnancy compared with pre‐pregnancy and (3) medication adherence among ICS users. Methods: We systematically searched literature in Embase, MEDLINE, CINAL and Cochrane, using terms related to asthma, pregnancy and medication use. All English articles reporting ICS among pregnant women with asthma were included. Prevalence, changes in ICS use during pregnancy and ICS adherence were pooled using STATA (version 15.0, StataCorp USA). Results: A total of 4237 references were retrieved in the initial search. Screening and review led to the inclusion of 52 articles for one or more aims (Aim 1: N = 45; Aim 2, N = 13; and Aim 3, N = 5). The pooled prevalence of ICS use during pregnancy was 41% (95%CI 36%‐45%); 49% (95%CI 44%‐55%) in Europe, 39% (95%CI 32%‐47%) in Australia and 34% (95%CI 27%‐41%) in North America. In eight prescription databases, ICS prescription rates lowered in the first trimester of pregnancy, compared with pre‐pregnancy, increased in the second trimester and decreased in the third trimester. Five studies reported ICS adherence among pregnant women, using four measures of self‐reported non‐adherence. In two comparable studies, pooled ICS non‐adherence was 40% (95%CI 36%‐44%). Conclusions: The prevalence of ICS use among pregnant women with asthma is 41% and varies widely between countries and continents, and prescription rates for ICS change throughout pregnancy. More studies are needed to investigate ICS adherence during pregnancy in women with asthma.
- Subject
- asthma; epidemiology; medication adherence; pregnancy; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1422894
- Identifier
- uon:37883
- Identifier
- ISSN:0954-7894
- Rights
- This is the peer reviewed version of the following article: Robijn, Annelies L.; Jensen, Megan E.; McLaughlin, Karen; Gibson, Peter G.; Murphy, Vanessa E. “Inhaled corticosteroid use during pregnancy among women with asthma: a systematic review and meta-analysis”. Clinical and Experimental Allergy Vol. 49, Issue 11, p. 1403-1417 (2019), which has been published in final form at http://dx.doi.org/10.1111/cea.13474. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
- Language
- eng
- Full Text
- Reviewed
- Hits: 1903
- Visitors: 1999
- Downloads: 161
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Author final version | 1000 KB | Adobe Acrobat PDF | View Details Download |